Treatment of Venous Thromboembolism

JAMA - Journal of the American Medical Association 311, 717 DOI: 10.1001/jama.2014.65

Citation Report

CITA	TIO	NL D	דתר

#	Article	IF	CITATIONS
1	Thrombosis: A major contributor to global disease burden. Thrombosis and Haemostasis, 2014, 112, 843-852.	1.8	28
2	Duration of Anticoagulation for Venous Thromboembolic Events. Circulation, 2014, 130, 2343-2348.	1.6	4
3	New insights into treatment of venous thromboembolism. Hematology American Society of Hematology Education Program, 2014, 2014, 297-305.	0.9	8
4	Thrombosis: A major contributor to global disease burden. Thrombosis Research, 2014, 134, 931-938.	0.8	119
5	Treatment of Acute Pulmonary Embolism: Update on Newer Pharmacologic and Interventional Strategies. BioMed Research International, 2014, 2014, 1-6.	0.9	13
6	Oral anticoagulants: new and improved. Blood, 2014, 124, 1851-1852.	0.6	2
7	Thrombosis: a major contributor to the global disease burden. Journal of Thrombosis and Haemostasis, 2014, 12, 1580-1590.	1.9	343
8	Global assays of hemostasis. Current Opinion in Hematology, 2014, 21, 395-403.	1.2	41
10	Therapies for Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2014, 311, 2543.	3.8	2
11	Venous thromboembolism: Diagnosis, treatment and the prevention of long-term complications. Reviews in Vascular Medicine, 2014, 2, 136-142.	0.4	0
13	Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2363-2371.	1.1	659
14	Prevention and Treatment of Venous Thromboembolism in Patients with IBD. Inflammatory Bowel Diseases, 2015, 21, 1204-1213.	0.9	28
15	The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods. American Heart Journal, 2015, 170, 447-454.e18.	1.2	13
16	Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. Drug Design, Development and Therapy, 2015, 9, 3557.	2.0	0
17	Depressive Symptoms as a Novel Risk Factor for Recurrent Venous Thromboembolism: A Longitudinal Observational Study in Patients Referred for Thrombophilia Investigation. PLoS ONE, 2015, 10, e0125858.	1.1	15
18	Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the <i>VTEval Project</i> . BMJ Open, 2015, 5, e008157.	0.8	19
19	Making headway in anticoagulant and antiplatelet therapy. Nature Reviews Cardiology, 2015, 12, 70-71.	6.1	8
20	Effectiveness of Inferior Vena Cava Filters on Mortality as an Adjuvant to Antithrombotic Therapy. American Journal of Medicine, 2015, 128, 312.e23-312.e31.	0.6	24

#	Article	IF	CITATIONS
21	Management of complications after rotator cuff surgery. Current Reviews in Musculoskeletal Medicine, 2015, 8, 40-52.	1.3	33
22	Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thrombosis Research, 2015, 136, 749-753.	0.8	78
23	Extrapolation of acenocoumarol pharmacogenetic algorithms. Vascular Pharmacology, 2015, 74, 151-157.	1.0	5
25	Antithrombotic and antiplatelet activities of orientin in vitro and in vivo. Journal of Functional Foods, 2015, 17, 388-398.	1.6	22
26	Aspirin in the primary prophylaxis of venous thromboembolism in surgical patients. Journal of the Royal College of Surgeons of Edinburgh, 2015, 13, 348-358.	0.8	22
27	Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants. Thrombosis and Haemostasis, 2015, 113, 1193-1202.	1.8	28
28	Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vascular Medicine, 2015, 20, 143-152.	0.8	25
29	Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis. Thrombosis Research, 2015, 136, 732-738.	0.8	18
30	Educational Level, Anticoagulation Quality, and Clinical Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study. PLoS ONE, 2016, 11, e0162108.	1.1	4
31	Heparin and anticoagulation. Frontiers in Bioscience - Landmark, 2016, 21, 1372-1392.	3.0	156
32	Systematic review of the complications following isolated calf deep vein thrombosis. British Journal of Surgery, 2016, 103, 789-796.	0.1	52
33	Deep vein thrombosis and pulmonary embolism. Lancet, The, 2016, 388, 3060-3073.	6.3	572
34	Wait—The Inferior Vena Cava IsÂThrombosed? Now What?. JACC: Cardiovascular Interventions, 2016, 9, 644-645.	1.1	1
35	Role of thromboxane-dependent platelet activation in venous thrombosis: Aspirin effects in mouse model. Pharmacological Research, 2016, 107, 415-425.	3.1	37
37	Orthopaedic nursing challenges in poly-traumatised patient management: A critical analysis of an Orthopaedic and Trauma Unit. International Journal of Orthopaedic and Trauma Nursing, 2016, 23, 60-71.	0.4	11
38	Venous Thromboembolic Disease in Children and Adolescents. Advances in Experimental Medicine and Biology, 2016, 906, 149-165.	0.8	10
39	Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Safety, 2016, 39, 1175-1187.	1.4	31
40	Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 554-564.	1.3	12

#	Article	IF	CITATIONS
41	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. Expert Opinion on Pharmacotherapy, 2016, 17, 2033-2047.	0.9	4
42	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology,the, 2016, 3, e379-e387.	2.2	136
43	Therapeutic anticoagulation in patients with traumatic brain injury. Journal of Surgical Research, 2016, 205, 186-191.	0.8	26
44	Antithrombotic and antiplatelet activities of small-molecule alkaloids from Scolopendra subspinipes mutilans. Scientific Reports, 2016, 6, 21956.	1.6	30
45	Thromboembolic disease and breathlessness. Current Opinion in Supportive and Palliative Care, 2016, 10, 249-255.	0.5	3
46	Efficacy of histotripsy combined with rt-PA <i>in vitro</i> . Physics in Medicine and Biology, 2016, 61, 5253-5274.	1.6	48
47	Contrast sonovenography – Is this the answer to complex deep vein thrombosis imaging?. Ultrasound, 2016, 24, 17-22.	0.3	7
48	Antithrombotic and antiplatelet activities of pelargonidin in vivo and in vitro. Archives of Pharmacal Research, 2016, 39, 398-408.	2.7	35
49	Pharmacology of anticoagulants used in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 15-31.	1.0	108
51	Prothrombin G20210A Mutation in a 53-Year-Old Male Patient with Deep Vein Thrombosis. Laboratory Medicine, 2016, 47, e12-e14.	0.8	1
52	Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis. Journal of General Internal Medicine, 2016, 31, 947-957.	1.3	53
53	Recent advances in anticoagulant drug delivery. Expert Opinion on Drug Delivery, 2016, 13, 421-434.	2.4	12
54	Is there a role yet for new direct oral anticoagulants in cancer patients?. Phlebology, 2016, 31, 157-159.	0.6	2
55	Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clinical Research in Cardiology, 2016, 105, 117-126.	1.5	60
56	Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 765-771.	0.7	10
57	Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency. Journal of General Internal Medicine, 2016, 31, 182-187.	1.3	18
58	Controversies in venous thromboembolism $\hat{a} \in $ " 2015. Blood Reviews, 2016, 30, 27-33.	2.8	8
59	SÃndrome de vena cava superior como complicación del tratamiento con inmunoglobulinas intravenosas. NeurologÃa, 2017, 32, 202-204.	0.3	1

		CITATION REP	PORT	
#	Article		IF	CITATIONS
61	The management of venous thromboembolism. Canadian Pharmacists Journal, 2017, 15), 81-89.	0.4	1
62	Identification of potential drug targets based on a computational biology algorithm for v thromboembolism. International Journal of Molecular Medicine, 2017, 39, 463-471.	enous	1.8	1
63	Rivaroxaban shows promise as effective therapy for cancer patients with venous thromb disease. Thrombosis Research, 2017, 152, 4-6.	oembolic	0.8	12
64	A decision model to estimate a risk threshold for venous thromboembolism prophylaxis i hospitalized medical patients. Journal of Thrombosis and Haemostasis, 2017, 15, 1132-1		1.9	15
65	Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adoles Pharmacotherapy, 2017, 37, e16-e20.	cent Patient.	1.2	6
66	Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based persp Pharmacological Research, 2017, 120, 206-218.	ective.	3.1	11
67	Superior vena cava syndrome as a complication of intravenous immunoglobulin treatme NeurologÃa (English Edition), 2017, 32, 202-204.	nt.	0.2	0
68	Inhibition of platelet aggregation and thrombosis by indole alkaloids isolated from the ec <i>Protaetia brevitarsis seulensis</i> (Kolbe). Journal of Cellular and Molecular Medicine, 1217-1227.	lible insect 2017, 21,	1.6	54
69	Antithrombotic properties of JJ1, a potent and novel thrombin inhibitor. Scientific Report 14862.	s, 2017, 7,	1.6	8
70	Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatn venous thromboembolism - A Danish nationwide cohort study. Scientific Reports, 2017,	nent of 7, 3347.	1.6	36
71	Paradoxical embolism. Medicine (United States), 2017, 96, e7332.		0.4	3
72	Ambulatory Versus In-Hospital Treatment of Proximal Lower-Limb Deep Vein Thrombosis Retrospective Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 859	in Adults: A -864.	0.7	3
73	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest, 2 564-571.	017, 151,	0.4	51
75	Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients. Biological Research for Nursing, 2017, 19, 198-205.		1.0	1
76	Aplastic anemia and risk of deep vein thrombosis and pulmonary embolism: A nationwide Thrombosis Research, 2017, 149, 70-75.	e cohort study.	0.8	5
77	Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. Thrombosis and Haemostasis, 2017, 117, 1182-1191.	5	1.8	35
78	Complications and Adverse Sequelae of Sclerotherapy. , 2017, , 200-261.			1
79	Asymptomatic Deep Vein Thrombosis during Free Flap: Concerns in Free Flap Surgery. Pl Reconstructive Surgery, 2018, 142, 551e-560e.	astic and	0.7	8

#	Article	IF	CITATIONS
80	Patients' Experience of Living with Cancer-associated thrombosis in Spain (PELICANOS). Supportive Care in Cancer, 2018, 26, 3233-3239.	1.0	25
82	Anticoagulation for Proximal Deep Vein Thrombosis. , 2018, , 299-313.		1
83	LncRNA WTAPP1 Promotes Migration and Angiogenesis of Endothelial Progenitor Cells via MMP1 Through MicroRNA 3120 and Akt/PI3K/Autophagy Pathways. Stem Cells, 2018, 36, 1863-1874.	1.4	63
84	Management of acute venous thromboembolism among a cohort of patients discharged directly from the emergency department. BMJ Open, 2018, 8, e022064.	0.8	5
85	Anticoagulant therapies for acute venous thromboembolism: a comparison between those discharged directly from the emergency department versus hospital in two Canadian cities. BMJ Open, 2018, 8, e022063.	0.8	5
86	Venous Disease. , 2018, , 354-358.		0
87	Real-world features associated with cancer-related venous thromboembolic events. ESMO Open, 2018, 3, e000363.	2.0	7
88	Delivery of thrombolytic therapy using rod-shaped plant viral nanoparticles decreases the risk of hemorrhage. Nanoscale, 2018, 10, 16547-16555.	2.8	30
90	Is anticoagulation for venous thromboembolism safe for Asian elective neurosurgical patients? A single centre study. ANZ Journal of Surgery, 2019, 89, 919-924.	0.3	5
91	Management of the Spinal Cord Injury in the Neurocritical Care Unit. , 2019, , 290-298.		0
92	Risks and Benefits of Anticoagulation in Cancer and Noncancer Patients. Seminars in Thrombosis and Hemostasis, 2019, 45, 629-637.	1.5	8
93	Discretionary Thrombophilia Test Acquisition and Outcomes in Patients With Venous Thromboembolism in a Realâ€World Clinical Setting. Journal of the American Heart Association, 2019, 8, e013395.	1.6	3
94	Long-Term Outcome of Catheter-Directed Thrombolysis in Pregnancy-Related Venous Thrombosis. Medical Science Monitor, 2019, 25, 3771-3777.	0.5	8
95	ACR Appropriateness Criteria® Radiologic Management of Venous Thromboembolism-Inferior Vena Cava Filters. Journal of the American College of Radiology, 2019, 16, S214-S226.	0.9	38
96	Thromboembolism and Bleeding. , 2019, , 1297-1316.		0
97	Policy Change for Deep Vein Thrombosis: Effects on Length of Stay and Hospitalization Costs of Moving From Warfarin to Direct Oral Anticoagulants. Clinical Therapeutics, 2019, 41, 269-279.	1.1	2
98	The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. American Journal of Emergency Medicine, 2020, 38, 1163-1170.	0.7	9
99	Should You Treat This Acutely III Medical Inpatient With Venous Thromboembolism Chemoprophylaxis?. Annals of Internal Medicine, 2020, 172, 484.	2.0	3

#	Article	IF	CITATIONS
100	Problems related with anticoagulant usage during COVID-19 outbreak. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 8, 695-696.	0.9	0
101	Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide. American Journal of Cardiovascular Drugs, 2020, 20, 301-309.	1.0	24
102	Ovarian vein thrombosis after coronavirus disease (COVID-19) infection in a pregnant woman: case report. Journal of Thrombosis and Thrombolysis, 2020, 50, 604-607.	1.0	32
103	Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2020, 20, 53.	0.7	1
104	A Case of Coronavirus Disease 2019 With Concomitant Acute Cerebral Infarction and Deep Vein Thrombosis. Frontiers in Neurology, 2020, 11, 296.	1.1	40
105	Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report. Journal of Thrombosis and Thrombolysis, 2020, 50, 229-232.	1.0	72
106	Risk factors associated with deep venous thrombosis in patients with different bed-rest durations: A multi-institutional case-control study. International Journal of Nursing Studies, 2021, 114, 103825.	2.5	10
107	Anticoagulation therapy in patients with traumatic brain injury: AnÂEastern Association for the Surgery of Trauma multicenter prospective study. Surgery, 2021, 169, 470-476.	1.0	9
108	Deep Vein Thrombosis and Pulmonary Embolus Thrombolysis and Endovascular Treatment. , 2021, , 531-542.		0
109	Diagnóstico y manejo actualizado del tromboembolismo pulmonar agudo. Revista Medica Sinergia, 2021, 6, e633.	0.0	0
110	A case report of greater saphenous vein thrombosis in a patient with coronavirus (COVID-19) infection. Tropical Diseases, Travel Medicine and Vaccines, 2021, 7, 6.	0.9	5
111	The Effectiveness of New Oral Anticoagulants in the Treatment of Lower Extremity Venous Thrombosis: A Retrospective Clinical Study. Konuralp Tip Dergisi, 0, , .	0.1	Ο
112	Oxygen Therapy Lowers Right Ventricular Afterload in Experimental Acute Pulmonary Embolism. Critical Care Medicine, 2021, 49, e891-e901.	0.4	8
113	Practice patterns surrounding referral to a specialty venous thromboembolism (VTE) clinic: a retrospective review. Journal of Thrombosis and Thrombolysis, 2022, 53, 176-181.	1.0	Ο
114	Deep Venous Thrombosis and Risk of Consequent Sepsis Event: A Retrospective Nationwide Population-Based Cohort Study. International Journal of Environmental Research and Public Health, 2021, 18, 7879.	1.2	5
115	Staged surgery for advanced cardiac intimal sarcoma involving the right atrium and the inferior vena cava. Journal of Cardiac Surgery, 2021, 36, 3973-3975.	0.3	3
116	THE EFFECTS OF GENETIC AND NON GENETIC FACTORS ON WARFARIN DOSE RESPONSE IN VENOUS THROMBOEMBOLISM. , 2021, , 4-5.		0
117	In Vivo Porcine Aged Deep Vein Thrombosis Model for Testing Ultrasound-based Thrombolysis Techniques. Ultrasound in Medicine and Biology, 2021, 47, 3447-3457.	0.7	4

#	Article	IF	CITATIONS
118	Clot Degradation Under the Action of Histotripsy Bubble Activity and a Lytic Drug. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2021, 68, 2942-2952.	1.7	9
119	Filter implantation for double inferior vena cava: A case report and literature review. World Journal of Emergency Medicine, 2021, 12, 332.	0.5	4
120	Trends in Imaging for Suspected Pulmonary Embolism Across US Health Care Systems, 2004 to 2016. JAMA Network Open, 2020, 3, e2026930.	2.8	24
121	Syntaxin-binding protein STXBP5 inhibits endothelial exocytosis and promotes platelet secretion. Journal of Clinical Investigation, 2014, 124, 4503-4516.	3.9	68
122	Unusual Presentation of Recurrent Pyogenic Bilateral Psoas Abscess Causing Bilateral Pulmonary Embolism by Iliac Vein Compression. American Journal of Case Reports, 2015, 16, 606-610.	0.3	9
123	Effect of Percutaneous Suction Thromboembolectomy on Improved Right Ventricular Function. Texas Heart Institute Journal, 2019, 46, 115-119.	0.1	3
124	Antitcoagulant and antiplatelet activities of scolymoside. BMB Reports, 2015, 48, 577-582.	1.1	40
125	Anticoagulation in patients with acute kidney injury undergoing kidney replacement therapy. Pediatric Nephrology, 2022, 37, 2303-2330.	0.9	6
126	Perioperative Management of a Patient with Hereditary Hemorrhagic Telangiectasia and Deep Vein Thrombosis: A Case Report. Journal of Anesthesia & Clinical Research, 2014, 05, .	0.1	0
128	The Efficiency of Hamilton Pretest Probability Value in Diagnosing Deep Vein Thrombosis. Clinical Medicine Research, 2015, 4, 43.	0.0	0
129	Fontan′s circulation with dextrocardia, recent pulmonary embolism, and inferior vena cava filter: Anesthetic challenges for urgent hysterectomy. Annals of Cardiac Anaesthesia, 2016, 19, 177.	0.3	0
130	Complications of Minimally Invasive Gynecologic Surgery. , 2016, , 419-464.		0
131	New Approaches for the Secondary Prevention of Cryptogenic Stroke Using Non-vitamin K Antagonist Oral Anticoagulants. , 2017, , 77-89.		0
132	Anticoagulation Following Anterior Cruciate Ligament Reconstruction. , 2017, , 87-101.		0
133	Impact of edoxaban approval for venous thromboembolism on length of hospitalization. Japanese Journal of Thrombosis and Hemostasis, 2017, 28, 50-54.	0.1	1
134	Venous Thromboembolism in the Intensive Care Unit. , 2017, , 221-232.		0
135	Venous Thromboembolism Associated with Foot and Ankle Surgery. , 2017, , 9-27.		0
136	Pulmonary embolism in multifield hospital: results of autopsy study. Vestnik Khirurgii Imeni I I Grekova, 2017, 176, 60-66.	0.0	2

		CITATION R	EPORT	
#	ARTICLE	2019 72 80	IF	CITATIONS
137	Stratifying Thromboembolic Risk: Why Is Your Patient on Antithrombotic Medications?. Bilateral Massive Pulmonary Embolism on Disseminated Intravascular Coagulation (DIV)		0.1	0
139	Postpartum Haemorrhage. Open Journal of Anesthesiology, 2018, 08, 85-92.			0
140	Prolonged Anticoagulation Therapy for venous Thromboembolism: Resolved Issuesand Questions. Flebologiya, 2019, 13, 42.	Controversial	0.2	1
141	Emergency conditions in vein disease. Naucni Casopis Urgentne Medicine - Halo 194, 20	019, 25, 61-77.	0.1	0
142	Effect of Inferior Vena Cava Filter on Venous Thromboembolism Mortality in Japan â€ JROAD-DPC Registry Analysis ―. Circulation Reports, 2019, 1, 296-302.	E• JROAD and	0.4	1
143	Assessment of risk factors in established cases of venous thrombosis. Indian Journal of Endovascular Surgery, 2020, 7, 415.	Vascular and	0.0	0
144	Anticoagulants and Antiplatelet Drugs. , 2021, , .			0
145	Venous Thromboembolism in the Intensive Care Unit. , 2020, , 189-199.			0
146	Venous Thromboembolic Disease in Children and Adolescents. Advances in Experimenta Biology, 2015, , .	l Medicine and	0.8	0
147	Percutaneous Thrombectomy with a Half-Deployed Stent for the Treatment of Acute Inf Cava Thrombosis. Vascular Specialist International, 2020, 36, 193-197.	erior Vena	0.2	0
148	Assessment of histological characteristics, imaging markers, and rt-PA susceptibility of evenous thrombi. Scientific Reports, 2021, 11, 22805.	εχ νίνο	1.6	8
149	In Vitro Testing of a Cobot System to Assist Histotripsy Clot Ablation. , 2020, , .			1
150	Risk assessment of venous thromboembolism and bleeding in COVIDâ€19 patients. Clir Journal, 2022, 16, 182-189.		0.6	34
151	A Fibrin Siteâ€Specific Nanoprobe for Imaging Fibrinâ€Rich Thrombi and Preventing Thr Venous Vessels. Advanced Materials, 2022, 34, e2109955. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Pra		11.1	10
152	in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, Consensus among Chinese experts on standard interventional therapy for deep venous	1181-1201.	2.3	43
153 154	lower extremity (second edition). Journal of Interventional Medicine, 2018, 1, 125-136. Catheter-Directed Thrombolysis for Postpartum Deep Venous Thrombosis. Frontiers in		0.2	2
	Cardiovascular Medicine, 2022, 9, 814057.			

#	Article	IF	CITATIONS
155	The Auxiliary Role of Heparin in Bone Regeneration and its Application in Bone Substitute Materials. Frontiers in Bioengineering and Biotechnology, 2022, 10, .	2.0	4
156	抗å‡å›ºç™,法ã«ã, ã,Šæ²»ç™,ã⊷ãŸè,œå,∙後å∵å\$äçå\$é™è" `ej€æ"ç—‡ã®1例(Massive inferior vena cava tl	hrombosis	after liver in
157	Drug-Related Problems and Factors Involved in the Imbalance of Oral Anticoagulants in Lebanese Patients: A Cross-Sectional Study. Dr Sulaiman Al Habib Medical Journal, 2022, 4, 77-85.	0.3	0
158	Impact of high altitude on the incidence of postoperative venous thromboembolism and its genetic susceptibility: A meta-analysis and systematic review. Science of the Total Environment, 2022, 838, 156632.	3.9	8
159	Prescribing Trends of Oral Anticoagulants from 2010 to 2020 in Shanghai, China: A Retrospective Study. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211325.	0.7	4
160	Fibrinolysis Shutdown and Hypofibrinolysis Are Not Synonymous Terms: The Clinical Significance of Differentiating Low Fibrinolytic States. Seminars in Thrombosis and Hemostasis, 2023, 49, 433-443.	1.5	4
161	Temporal trend in venous thromboembolism hospitalization rates in Brazilian older adults, 2010–2020. Journal of Thrombosis and Thrombolysis, 0, , .	1.0	0
162	Protocol for a modelling study to assess the clinical and cost-effectiveness of indefinite anticoagulant therapy for first unprovoked venous thromboembolism. BMJ Open, 2023, 13, e053927.	0.8	1
163	Venous thromboembolism and risk of depression: aÂpopulation-based cohort study. Journal of Thrombosis and Haemostasis, 2023, 21, 953-962.	1.9	2
164	One filter may be enough for duplicate inferior vena cava filter implantation in patients with deep venous thrombosis: Two cases report. Medicine (United States), 2022, 101, e32480.	0.4	0
165	Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives. Journal of Medicinal Chemistry, 2023, 66, 5332-5363.	2.9	3
166	Efficacy and safety of salvianolate and enoxaparin in the prevention of perioperative deep venous thrombosis in gastrointestinal surgery. PACE - Pacing and Clinical Electrophysiology, 0, , .	0.5	0
167	Pulmonary thromboembolism in patients with stroke: the results of the clinical-anatomic analysis. Buletinul AŞM: Ştiinţe Medicale, 2022, 74, 75-79.	0.0	0
169	Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism. Clinical and Translational Science, 2023, 16, 946-954.	1.5	0
170	Ovarian Vein Thrombosis: A Sequela of COVID-Associated Coagulopathy. Cureus, 2023, , .	0.2	1
174	Venous Thromboembolism: Review of Clinical Challenges, Biology, Assessment, Treatment, and Modeling. Annals of Biomedical Engineering, 2024, 52, 467-486.	1.3	1